Skip to main content

Table 2 LOT transition among patients with > 1 LOT

From: A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US

LOT1 LOT2
(N = 229)
Pazopanib Docetaxel, gemcitabine Doxorubicin Gemcitabine Temozolomide Others
(N = 43, 18.8%) (N = 38, 16.6%) (N = 24, 10.5%) (N = 9, 3.9%) (N = 8, 3.5%) (N = 107, 46.7%)
n % n % n % n % n % n %
Docetaxel, gemcitabine 20 46.5 5 13.2 14 58.3 0 0.0 0 0.0 19 17.8
Doxorubicin 4 9.3 12 31.6 1 4.2 1 11.1 2 25.0 13 12.2
Pazopanib 3 7.0 4 10.5 1 4.2 3 33.3 2 25.0 4 3.7
Doxorubicin, ifosfamide 3 7.0 5 13.2 0 0.0 1 11.1 0 0.0 2 1.9
Gemcitabine 2 4.7 0 0.0 0 0.0 0 0.0 0 0.0 6 5.6
Others 11 25.6 12 31.6 8 33.3 4 44.4 4 50.0 63 58.9
LOT2 LOT3
(N = 88)
Pazopanib Doxorubicin Eribulin mesylate Docetaxel, gemcitabine Temozolomide Others
(N = 27, 30.7%) (N = 12, 13.6%) (N = 6, 6.8%) (N = 5, 5.7%) (N = 4, 4.5%) (N = 34, 38.6%)
n % n % n % n % n % n %
Pazopanib 4 14.8 5 41.7 0 0.0 0 0.0 2 50.0 5 14.7
Docetaxel, gemcitabine 8 29.6 2 16.7 0 0.0 1 20.0 0 0.0 2 5.9
Doxorubicin 4 14.8 1 8.3 1 16.7 1 20.0 0 0.0 4 11.8
Gemcitabine 1 3.7 2 16.7 0 0.0 0 0.0 0 0.0 2 5.9
Temozolomide 2 7.4 0 0.0 0 0.0 1 20.0 0 0.0 3 8.8
Others 8 29.6 2 16.7 5 83.3 2 40.0 2 50.0 18 52.9